23 March 2018

New Clinical Step for a Drug Candidate from Acasti Pharma

Acasti Pharma has completed a new step in phase 3 of the clinical studies on its drug candidate CaPre: The company announced that a first patient – out of a total of 500 – was randomly selected.

CaPre, an omega-3 phospholipid derived from krill oil, is used in the treatment of severe hypertriglyceridemia, a disease that causes high blood triglyceride levels and may increase the risk of coronary diseases and pancreatitis.

Results from the TRILOGY clinical program on the safety and effectiveness of the drug candidate are expected for the end of 2019.

The first two phases of clinical studies were conclusive, and the medication could soon be used to help numerous people suffering from severe hypertriglyceridemia, estimated at 3 to 4 million people in the United States, according to the American Heart Association.

» Read full article for more details

Source : Acasti Pharma

Back to the news

Leave a Reply

Your email address will not be published. Required fields are marked *


Sherbrooke Innopole is moving to the Quartier général de l’entrepreneuriat!

As of November 20, 2023, our addresses – physical and mailing – will change. Please consult them here.

Our team will mainly be teleworking during the moving phase, from November 20 to 30. We invite you to contact our professionals by email or telephone before coming to our offices.

We look forward to welcoming you to the QG on December 4!